Global Glioblastoma Treatment Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Glioblastoma Treatment Market Segmentation, By Types (Primary, and Secondary), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) - Industry Trends and Forecast to 2032

Glioblastoma Treatment Market Size

• The global glioblastoma treatment market size was valued at USD 3.05 billion in 2024 and is expected to reach USD 6.22 billion by 2032, at a CAGR of 9.30% during the forecast period
• The market growth is largely fueled by the increasing incidence of glioblastoma worldwide, coupled with advancements in oncology research and drug development, driving demand for effective treatment options
• Furthermore, rising patient demand for targeted therapies, immunotherapies, and combination treatment approaches is establishing novel glioblastoma treatment solutions as the preferred choice. These converging factors are accelerating the adoption of innovative therapies, thereby significantly boosting the industry’s growth

Glioblastoma Treatment Market Analysis

• Glioblastoma treatment, encompassing therapies such as surgery, radiation, chemotherapy, and emerging targeted and immunotherapies, is increasingly recognized as a critical area of oncology due to the aggressive nature of the disease and its high recurrence rate
• The escalating demand for effective glioblastoma treatment is primarily fueled by rising prevalence rates, advancements in neuro-oncology research, the development of novel therapeutics, and growing awareness among patients and healthcare providers regarding early diagnosis and management
• North America dominated the glioblastoma treatment market with the largest revenue share of 41.5% in 2024, supported by advanced healthcare infrastructure, robust clinical trial activity, and strong presence of leading pharmaceutical and biotech companies. The U.S. experienced substantial growth driven by the availability of specialized neuro-oncology centers, higher adoption of innovative therapies, and favorable reimbursement frameworks
• Asia-Pacific is expected to be the fastest growing region in the glioblastoma treatment market during the forecast period, fueled by a rapidly expanding patient pool, increasing investments in healthcare infrastructure, and rising participation in clinical research across countries such as China, India, and Japan
• The hospital segment dominated the glioblastoma treatment market with a revenue share of 46.1% in 2024, supported by the availability of comprehensive neuro-oncology services, advanced surgical facilities, and multidisciplinary treatment teams

Report Scope and Glioblastoma Treatment Market Segmentation    

Glioblastoma Treatment Market Trends

Advancements in Targeted and Personalized Therapies

• A significant and accelerating trend in the global glioblastoma treatment market is the growing focus on targeted therapies, immunotherapies, and personalized treatment approaches. This shift is aimed at improving patient outcomes, minimizing side effects, and extending overall survival in a disease known for its aggressive progression

  • For instance, ongoing clinical trials are investigating novel monoclonal antibodies, checkpoint inhibitors, and tumor-treating fields, which offer more precise mechanisms of action compared to traditional chemotherapy and radiotherapy. These advancements are expected to improve response rates and quality of life for patients

• Integration of molecular profiling and genomic analysis into clinical decision-making is enabling oncologists to tailor treatment regimens based on individual tumor characteristics. Personalized approaches allow for better prediction of treatment efficacy and risk of recurrence, which is becoming a key differentiator in glioblastoma care
• The expansion of specialized neuro-oncology centers and multidisciplinary treatment teams facilitates comprehensive care, including surgical resection, radiotherapy, chemotherapy, and supportive therapies, providing a coordinated and patient-centric approach
• This trend towards innovative, evidence-based, and personalized treatment strategies is fundamentally reshaping patient expectations and clinical standards in glioblastoma management. Consequently, pharmaceutical and biotech companies are investing in research and development of novel therapeutic options to address unmet medical needs
• The demand for advanced glioblastoma therapies is growing rapidly across both developed and emerging markets, as rising prevalence rates, increasing patient awareness, and better access to specialty care drive adoption of innovative treatment solutions

Glioblastoma Treatment Market Dynamics

Driver

Growing Need Due to Rising Disease Burden and Advancements in Therapies

• The increasing prevalence of glioblastoma, coupled with rising awareness of advanced treatment options, is a significant driver for the heightened demand for innovative therapies

  • For instance, in April 2024, a leading pharmaceutical company announced the launch of a novel targeted therapy designed to improve progression-free survival and quality of life for glioblastoma patients. Such strategies by key players are expected to drive the Glioblastoma Treatment industry growth in the forecast period

• As patients and healthcare providers seek more effective solutions, advanced treatment options such as immunotherapies, tumor-treating fields, and combination regimens are becoming preferred over conventional therapies, offering improved efficacy and tolerability
• Furthermore, the expansion of specialized neuro-oncology centers and multidisciplinary care teams is enhancing access to state-of-the-art treatment options, enabling comprehensive management of glioblastoma
• The growing availability of patient-centric therapies, coupled with increasing clinical trial participation and adoption of novel drug formulations, is propelling the uptake of glioblastoma treatments in both hospital and specialty clinic settings

Restraint/Challenge

High Treatment Costs and Limited Access to Advanced Therapies

• The high cost of advanced glioblastoma treatments poses a significant challenge to widespread adoption, particularly in price-sensitive regions or for patients without comprehensive insurance coverage
• Access to specialized treatment centers and novel therapies may be limited in developing countries or rural areas, delaying timely intervention and affecting overall outcomes
• Addressing these challenges through the development of more cost-effective therapies, expansion of treatment infrastructure, and improved patient awareness programs will be crucial for sustaining market growth
• While new therapies offer enhanced survival and quality-of-life benefits, the perceived complexity and need for specialized administration can still hinder adoption, especially among patients with limited access to comprehensive care facilities
• Limited reimbursement policies and varying insurance coverage across regions can restrict patient access to innovative glioblastoma therapies, affecting overall market penetration
• The side effects associated with certain aggressive treatment regimens, including chemotherapy and radiotherapy, may reduce patient compliance, limiting the widespread adoption of some advanced treatment options
• Continued investment in research, education, and infrastructure will be vital to overcoming these barriers and ensuring equitable access to effective glioblastoma treatments globally

Glioblastoma Treatment Market Scope

The market is segmented on the basis of treatment type, route of administration, application, and end-user.

• By Treatment Type

On the basis of treatment type, the glioblastoma treatment market is segmented into medication, surgery, and therapy. The medication segment dominated the largest market revenue share of 45.3% in 2024, driven by the widespread use of chemotherapeutic agents, targeted therapies, and immunotherapy regimens. Increasing clinical evidence supporting the efficacy of novel drugs, coupled with the convenience of outpatient administration, is propelling the growth of this segment. Pharmaceutical innovations, including oral and parenteral formulations with improved safety profiles, are enhancing patient adherence and outcomes. The growing prevalence of glioblastoma and the focus on early intervention further drive the preference for pharmacological solutions. Medication treatments are also increasingly supported by specialized neuro-oncology centers, boosting accessibility for patients across different regions. Moreover, healthcare providers are emphasizing combination therapies that integrate medications with other treatment modalities, creating additional demand for the medication segment. The segment is further strengthened by continuous investment in research and development, leading to the introduction of drugs with fewer side effects and enhanced efficacy.

The surgery segment is expected to witness the fastest CAGR of 7.8% from 2025 to 2032, fueled by advances in minimally invasive neurosurgical techniques, intraoperative imaging, and precision tumor resection. Surgical interventions are preferred for eligible patients to reduce tumor burden, enhance survival rates, and improve quality of life. Technological developments in neuronavigation, robotic-assisted surgery, and intraoperative monitoring are further accelerating adoption. Surgeons increasingly recommend combining surgical resection with adjunct therapies, increasing the segment’s overall growth potential. Rising patient awareness and improvements in post-operative care are also contributing to the expansion of the surgical segment. In addition, the growing availability of specialized neurosurgical centers in both developed and emerging markets is making surgery a more accessible and practical option for glioblastoma patients. The adoption of advanced anesthesia and perioperative management protocols also contributes to the faster growth of the surgical segment.

• By Route of Administration

On the basis of route of administration, the glioblastoma treatment market is segmented into oral, parenteral, and others. The oral segment dominated the largest revenue share of 42.8% in 2024, driven by patient preference for non-invasive administration and the convenience of self-administered treatment. Oral therapies, including targeted drugs and chemotherapeutic agents, are favored for outpatient management and long-term therapy adherence. The segment benefits from continuous pharmaceutical innovation, regulatory approvals, and increasing patient awareness of treatment options. The ability to combine oral medications with adjunct therapies such as radiotherapy further strengthens market demand. Health systems are also supporting oral treatment through reimbursement schemes and patient assistance programs, ensuring broader accessibility. Patient compliance programs, digital monitoring tools, and caregiver support services further enhance the appeal of oral therapy, contributing to sustained market dominance.

The parenteral segment is expected to witness the fastest CAGR of 8.3% from 2025 to 2032, propelled by the growing adoption of intravenous and intratumoral therapies for aggressive glioblastoma cases. Parenteral administration ensures rapid drug delivery, high bioavailability, and precise dosing, making it suitable for hospital-based treatments. Emerging biologics and immunotherapies administered parenterally are gaining traction due to improved clinical outcomes. The increasing number of specialty clinics equipped for intravenous therapies, combined with ongoing research into novel delivery mechanisms, is fueling growth. Patient monitoring and supportive care infrastructure in hospitals further facilitate the adoption of parenteral therapies. The segment is also supported by increasing physician awareness, ongoing training in advanced administration techniques, and the introduction of next-generation infusion systems that enhance safety and efficiency.

• By Application

On the basis of application, the glioblastoma treatment market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospital segment dominated the largest revenue share of 46.1% in 2024, supported by the availability of comprehensive neuro-oncology services, advanced surgical facilities, and multidisciplinary treatment teams. Hospitals provide integrated care combining surgery, medication, and radiation therapy, catering to both initial and recurrent glioblastoma cases. The presence of clinical trial programs and access to cutting-edge therapies further strengthens the hospital segment. Patients often prefer hospitals for their comprehensive diagnostic, therapeutic, and post-treatment monitoring capabilities, enhancing market penetration. In addition, hospitals provide advanced supportive care, rehabilitation services, and access to palliative care programs, which further enhance the segment’s appeal.

The specialty clinics segment is expected to witness the fastest CAGR of 9.2% from 2025 to 2032, driven by increasing outpatient services, focused neuro-oncology care, and personalized treatment plans. Specialty clinics offer convenient access to targeted therapies, immunotherapy, and follow-up care, allowing patients to receive consistent management without prolonged hospital stays. The growing number of private clinics equipped with advanced imaging and treatment technologies, combined with rising patient awareness, is accelerating adoption. Partnerships with pharmaceutical companies and clinical trial participation also contribute to the growth of specialty clinics. The segment benefits from improved patient education, telemedicine services, and streamlined treatment protocols that enhance patient convenience and optimize clinical outcomes.

• By End-User

On the basis of end-user, the glioblastoma treatment market is segmented into hospitals, specialty clinics, homecare, and others. The hospital segment dominated the market in 2024 with a revenue share of 48.7%, due to centralized treatment facilities, advanced equipment, and the ability to manage complex glioblastoma cases efficiently. Hospitals provide integrated patient care that encompasses diagnosis, surgery, and post-operative therapy. Hospitals also facilitate multidisciplinary collaboration among oncologists, neurosurgeons, radiologists, and rehabilitation specialists, further strengthening this segment’s dominance.

The homecare segment is expected to witness the fastest CAGR of 10.1% from 2025 to 2032, supported by the increasing adoption of home-based care services, telemedicine, and patient preference for treatment in the comfort of their own homes. Homecare enables continuous monitoring and medication management for post-surgical and long-term therapy patients, driving rapid growth in this segment. The segment is further bolstered by digital health technologies, remote consultation platforms, and patient support programs that enable effective management outside hospital settings. Homecare solutions are particularly appealing in regions with limited access to specialized hospitals, contributing to faster adoption and market expansion.

Glioblastoma Treatment Market Regional Analysis

• North America dominated the glioblastoma treatment market with the largest revenue share of 41.5% in 2024, supported by advanced healthcare infrastructure, robust clinical trial activity, and a strong presence of leading pharmaceutical and biotechnology companies
• The market experienced substantial growth due to the availability of specialized neuro-oncology centers, higher adoption of innovative therapies, and favorable reimbursement frameworks
• Increasing awareness among patients and caregivers, coupled with early diagnosis and personalized treatment approaches, further drives the demand for advanced glioblastoma treatment solutions

U.S. Glioblastoma Treatment Market Insight

The U.S. glioblastoma treatment market captured the largest revenue share in North America in 2024, driven by advanced healthcare infrastructure, a high prevalence of brain tumors, and substantial investment in neuro-oncology. The country benefits from specialized treatment centers, robust clinical trial activity, and the adoption of innovative therapies including targeted therapy and immunotherapy. Favorable reimbursement frameworks and growing patient awareness further support market expansion. In addition, the increasing integration of advanced diagnostic technologies and personalized treatment approaches is contributing to the rapid growth of the U.S. glioblastoma treatment market.

Europe Glioblastoma Treatment Market Insight

The Europe glioblastoma treatment is projected to expand at a significant CAGR throughout the forecast period, driven by an increasing emphasis on early diagnosis, government support for oncology programs, and the rising prevalence of brain tumors. Countries such as Germany, France, and the U.K. are witnessing substantial growth due to the development of specialized treatment centers, ongoing clinical research, and the adoption of novel therapies. Improved healthcare infrastructure and patient access to innovative treatment options are further fueling market expansion across the region.

U.K. Glioblastoma Treatment Market Insight

The U.K. glioblastoma treatment is anticipated to grow at a notable CAGR during the forecast period, supported by strong public and private healthcare initiatives, early intervention strategies, and a rising focus on research and development in oncology. Increased awareness of glioblastoma, coupled with the availability of specialized care centers and clinical trials, is encouraging patient adoption of innovative therapies.

Germany Glioblastoma Treatment Market Insight

The Germany glioblastoma treatment is expected to expand at a considerable CAGR during the forecast period, driven by advanced healthcare infrastructure, growing government investment in neuro-oncology, and the adoption of targeted therapies. The presence of well-established pharmaceutical companies and ongoing clinical research initiatives are further contributing to the growth of the market.

Asia-Pacific Glioblastoma Treatment Market Insight

The Asia-Pacific glioblastoma treatment is expected to register the fastest CAGR during the forecast period, fueled by a rapidly expanding patient pool, increasing healthcare infrastructure investment, and rising participation in clinical research in countries such as China, India, and Japan. The growing prevalence of brain tumors, coupled with greater awareness of innovative treatment options, is supporting market adoption. Expanding neuro-oncology centers, government support for oncology programs, and improved reimbursement frameworks are key factors accelerating growth in this region.

Japan Glioblastoma Treatment Market Insight

The Japan glioblastoma treatment is gaining momentum due to the country’s advanced healthcare system, increasing patient awareness, and the rising number of neuro-oncology centers. The focus on early diagnosis, innovative therapy adoption, and government initiatives to enhance cancer care infrastructure is expected to drive market growth in the coming years.

China Glioblastoma Treatment Market Insight

The China glioblastoma treatment accounted for the largest revenue share in Asia-Pacific in 2024, attributed to the country’s expanding healthcare access, rising middle-class population, and increasing investment in neuro-oncology infrastructure. Rapid urbanization, growth in specialized treatment centers, and enhanced participation in clinical trials are driving market adoption. Moreover, supportive government policies and increasing awareness among patients and caregivers are facilitating the uptake of advanced glioblastoma treatment options.

Glioblastoma Treatment Market Share

The Glioblastoma Treatment industry is primarily led by well-established companies, including:

• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson and its affiliates (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Amneal Pharmaceuticals LLC. (U.S.)

Latest Developments in Global Glioblastoma Treatment Market

• In November 2021, MimiVax, LLC received a “Study May Proceed” notification from the U.S. FDA to initiate a Phase 2b clinical trial of SurVaxM in newly diagnosed glioblastoma patients. This milestone marked a significant advancement in personalized cancer treatment, offering new hope for patients with this aggressive brain tumor
• In February 2022, Roswell Park Comprehensive Cancer Center launched a Phase 2b randomized clinical trial of SurVaxM in newly diagnosed glioblastoma patients. This trial aimed to evaluate the efficacy and safety of the vaccine, potentially establishing it as a new standard of care in glioblastoma treatment
• In March 2025, DCVax-L, a personalized vaccine for glioblastoma multiforme, demonstrated significant results in Phase 3 clinical trials, showing substantial improvements in median survival for both newly diagnosed and relapsed patients. Northwest Biotherapeutics submitted a marketing authorization application in the UK, with approval expected to follow in the U.S.
• In June 2025, Gilead Sciences, in collaboration with the University of Pennsylvania, reported promising results from a dual-target CAR-T cell therapy for recurrent glioblastoma. The therapy led to tumor shrinkage in 62% of patients, with some experiencing disease stability for over a year
• In June 2025, researchers at the University of Southern California initiated a Phase 3 trial testing a combination of electric fields and immune therapy for glioblastoma. The trial aimed to enroll over 740 patients across the U.S., Europe, and Israel, evaluating the potential of this novel approach to enhance treatment outcomes
• In June 2025, scientists at the Medical College of Wisconsin advanced a Phase 2 clinical trial for gallium maltolate (GaM), an oral medication targeting iron metabolism in cancer cells. Early Phase 1 results indicated the drug was well-tolerated in heavily pretreated glioblastoma patients, paving the way for further studies
• In April 2025, the Christie NHS Trust in Manchester launched the Portrait trial, investigating the use of Tumour Treating Fields (TTFields) therapy earlier in glioblastoma treatment. The trial aimed to determine if initiating TTFields before surgery could improve patient outcomes, challenging conventional treatment timelines

SKU-54140